Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
| HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
|---|---|---|---|---|---|
| 10249-1 | Epirubicin | Ellence | LSM-2078 |  | 41867 |
| 10097-3 | Erlotinib | OSI-774 | LSM-1097 |  | 176870 |
| 10250-1 | Etoposide | LSM-6348 |  | 36462 | |
| 10235-2 | Everolimus | RAD001 | LSM-4258 |  | 53398658 |
| 10251-1 | Fascaplysin | LSM-4272 |  | 73293 | |
| 10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 |  | 11493598 |
| 10508-1 | FTase Inhibitor I | B581 |  | 132887 | |
| 10098-2 | Gefitinib | ZD1839; Iressa | LSM-1098 |  | 123631 |
| 10108-2 | Geldanamycin | LSM-42789 |  | 644250 | |
| 10252-1 | Gemcitabine | Gemzar | LSM-5333 |  | 60750 |
| 10253-1 | Glycyl-H-1152 | LSM-4274 |  | ||
| 10509-1 | GM6001 | Ilomastat; Galardin; GM-6001 |  | 132519 | |
| 10062-3 | GSK1070916 | KIN001-216 | LSM-1062 |  | 46885626 |
| 10255-1 | GSK1838705A | LSM-4276 |  | 25182616 | |
| 10013-3 | GSK461364 | GSK461364A | LSM-1013 |  | 15983966 |
| 10257-1 | GSK923295 | LSM-4278 |  | 68651179 | |
| 10029-2 | GW-5074 | LSM-1029 |  | 5034 | |
| 10014-3 | GW843682X | GW843682 | LSM-1014 |  | 9826308 |
| 10258-1 | Ibandronate | Boniva | LSM-4279 |  | 44828485 |
| 10259-1 | ICRF-193 | LSM-4280 |  | 115150 | |
| 10228-2 | IKK16 | LSM-2309 |  | 9549298 | |
| 10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 |  | 5291 |
| 10260-1 | Ispinesib | SB-715992 | LSM-5732 |  | 6851740 |
| 10261-1 | Ixabepilone | Azaepothilone B; Ixempra | LSM-43293 |  | 216344 |
| 10208-2 | JNK-IN-5A | TCS JNK 5a; KIN001-188 | LSM-1209 |  | 766949 |